** Shares of Cochlear COH.AX fall as much as 1.3% to A$309.090
** Shares of the healthcare technology co set for their weakest week since December 9, 2024, if losses hold
** The priciest stock in ASX is tracking losses seen by the country's healthcare sub-index .AXHJ, which is down 0.7%
** UBS hikes stock's price target to A$270 from A$265, retains "sell" rating
** Brokerage made changes to their foreign exchange estimates, underlying assumptions are unchanged
** Three of 15 analysts rate the stock "buy" or higher, 10 "hold" and two "sell"; their median PT is A$305.00 – LSEG data
** Stock fell 8.8% in 2024
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.